Patents by Inventor Yoko Kayukawa

Yoko Kayukawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Drug conjugate comprising anti-CDH3 (P-cadherin) antibody
    Patent number: 9764041
    Abstract: It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: September 19, 2017
    Assignee: PERSEUS PROTEOMICS INC.
    Inventors: Keisuke Ishii, Katsuyuki Mitomo, Katsushi Kouda, Fumiko Nomura, Yoko Kayukawa, Tadashi Matsuura
  • Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof
    Patent number: 9644028
    Abstract: The present invention provides an anti-CDH3 humanized antibody having lower immunogenicity, and an anti-CDH3 humanized antibody drug conjugate having the aforementioned anti-CDH3 humanized antibody. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody having complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: May 9, 2017
    Assignee: PERSEUS PROTEOMICS INC.
    Inventors: Keisuke Ishii, Katsuyuki Mitomo, Katsushi Kouda, Fumiko Nomura, Yoko Kayukawa, Tadashi Matsuura
  • ANTI-CDH3 HUMANIZED ANTIBODY, DRUG CONJUGATE THEREOF, AND USE THEREOF
    Publication number: 20160152703
    Abstract: It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 2, 2016
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Keisuke ISHII, Katsuyuki MITOMO, Katsushi KOUDA, Fumiko NOMURA, Yoko KAYUKAWA, Tadashi MATSUURA
  • DRUG CONJUGATE COMPRISING ANTI-CDH3 (P-CADHERIN) ANTIBODY
    Publication number: 20160058883
    Abstract: It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.
    Type: Application
    Filed: April 4, 2012
    Publication date: March 3, 2016
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Keisuke ISHII, Katsuyuki MITOMO, Katsushi KOUDA, Fumiko NOMURA, Yoko KAYUKAWA, Tadashi MATSUURA
  • Anti-human P-cadherin (CDH3) recombinant antibody
    Patent number: 9127061
    Abstract: It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: September 8, 2015
    Assignee: PERSEUS PROTEOMICS INC.
    Inventors: Lilin Zhang, Katsuyuki Mitomo, Katsushi Kouda, Yoko Kayukawa
  • Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
    Patent number: 9017683
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 28, 2015
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
  • ANTI-HUMAN P-CADHERIN (CDH3) RECOMBINANT ANTIBODY
    Publication number: 20140221620
    Abstract: It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells.
    Type: Application
    Filed: June 19, 2012
    Publication date: August 7, 2014
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Lilin Zhang, Katsuyuki Mimoti, Katsushi Kouda, Yoko Kayukawa
  • HIGHLY EFFECTIVE ANTI-CADHERIN ANTIBODY FOR INDUCTION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY IN VIVO
    Publication number: 20130245232
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: May 3, 2013
    Publication date: September 19, 2013
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
  • HIGHLY EFFECTIVE ANTI-CADHERIN ANTIBODY FOR INDUCTION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY IN VIVO
    Publication number: 20130243771
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: May 3, 2013
    Publication date: September 19, 2013
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
  • Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
    Patent number: 8455249
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: June 4, 2013
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
  • ANTI-CADHERIN ANTIBODY
    Publication number: 20120136140
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.
    Type: Application
    Filed: April 30, 2010
    Publication date: May 31, 2012
    Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishi, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa